<code id='37688E97EB'></code><style id='37688E97EB'></style>
    • <acronym id='37688E97EB'></acronym>
      <center id='37688E97EB'><center id='37688E97EB'><tfoot id='37688E97EB'></tfoot></center><abbr id='37688E97EB'><dir id='37688E97EB'><tfoot id='37688E97EB'></tfoot><noframes id='37688E97EB'>

    • <optgroup id='37688E97EB'><strike id='37688E97EB'><sup id='37688E97EB'></sup></strike><code id='37688E97EB'></code></optgroup>
        1. <b id='37688E97EB'><label id='37688E97EB'><select id='37688E97EB'><dt id='37688E97EB'><span id='37688E97EB'></span></dt></select></label></b><u id='37688E97EB'></u>
          <i id='37688E97EB'><strike id='37688E97EB'><tt id='37688E97EB'><pre id='37688E97EB'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:entertainment    Page View:21

          What does it mean to a bad CEO? Can biotech endure another election year? And can you go to too many J.P. Morgan parties?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our last episode of 2023, so we look back on the biggest stories of the year, discuss the best and worst CEOs in the industry, and make some reasonably informed guesses on what 2024 has in store for the drug industry.

          advertisement

          For more on what we cover, here are the year’s best CEOs; here are the worst; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          Astellas still sees hope in its gene therapy after four deaths
          Astellas still sees hope in its gene therapy after four deaths

          AdobeAgenetherapystudy,haltedwhenfourchildrenwitharareneuromusculardisorderdiedaftertreatment,showed

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

          INAFASSBENDER/AFPviaGettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup tog